A Phase 2, Prospective, Randomized, Double-Masked, Active- Comparator Controlled, Multi-center Study to Investigate the Efficacy and Safety of Repeated Intravitreal Administration of KSI-301 in Subjects with Neovascular (Wet) Age-Related Macular Degeneration